W. Meyer‐Sabellek - Concepedia

Author

W. Meyer‐Sabellek

Also Known As

Meyer-Sabellek, W A Meyer-Sabellek, W MEYERSABELLEK, W MEYER‐SABELLEK, W Meyer-Sabellek, W. A. Meyer-Sabellek, W. MEYER‐SABELLEK, W. Meyer-Sabellek, W. Meyer‐Sabellek

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Diakonie Klinikum Jung-Stilling AstraZeneca (Germany)Bayreuth Medical Center Otto-von-Guericke University Magdeburg

About

W. Meyer‐Sabellek is an author at Charité - Universitätsmedizin Berlin specializing in medicine, cardiovascular disease, and hypertension.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	407
2	Health Sciences	4	4	109
3	Engineering	3	3	62
4	Public Health	2	2	195
5	Applied Physiology	1	1	32

W. Meyer‐Sabellek

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Prevalence of extra‐oesophageal manifestations in gastro‐oesophageal reflux disease: an analysis based on the ProGERD Study D Jaspersen, Michael Kulig, Joachim Labenz, Alimentary Pharmacology & Therapeutics	2003	282
Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiative Michael Kulig, Andreas Leodolter, Michael Vieth, Alimentary Pharmacology & Therapeutics	2003	251
Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study Michael Kulig, Marc Nocon, Michael Vieth, Journal of Clinical Epidemiology EsophagusClinical EpidemiologyGastroenterologyRiskGastroesophageal Reflux Disease	2004	156
Consensus document on non-invasive ambulatory blood pressure monitoring A Amery, Hans R. Brunner, D Clément, Blood Pressure MonitoringHypertensionPressure MeasurementBlood Pressure VariabilityMedicine	1990	86
What Parameters Are Relevant for the Histological Diagnosis of Gastroesophageal Reflux Disease without Barrett’s Mucosa? Michael Vieth, U Peitz, Joachim Labenz, Digestive Diseases	2004	57
Antihypertensive and metabolic effects of diltiazem and nifedipine. Karl-Ludwig Schulte, W. Meyer‐Sabellek, A Haertenberger, Hypertension HypertensionCardiovascular PharmacologyPharmacotherapyDiastolic FunctionBlood Pressure	1986	54
Alkaline phosphatase. Laboratory and clinical implications. W. Meyer‐Sabellek, Pranav Sinha, E. Köttgen PubMed	1988	52
Cost‐of‐disease analysis in patients with gastro‐oesophageal reflux disease and Barrett's mucosa Stefan N. Willich, Marc Nocon, Michael Kulig, Alimentary Pharmacology & Therapeutics	2006	51
The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing Roland Buhl, Péter Kardos, Kai Richter, Current Medical Research and Opinion	2004	42
Is patient self-report an adequate tool for monitoring cardiovascular conditions in patients with hypercholesterolemia? Heike Englert, Jacqueline Müller‐Nordhorn, Stefan Seewald, Journal of Public Health Heart FailureCardiometabolic RiskAdequate ToolCase Report FormsHyperlipidemia	2010	39

Page 1